Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by carduon May 30, 2006 11:26am
365 Views
Post# 10921192

Take note !!

Take note !!Here's what can happen when a company runs out of cash and the predators circle.The shareholders,invariably,get the shaft. "99.9% of companies trading in bankruptcy protection usually wipe out the old common shares. Don't get burned buying this worthless paper. Read this key line in the Globe today saying the stock is more than likely to be worthless: "Operating under court-appointed receivership since December, Hemosol has previously warned that its stock is likely to be worth little or nothing if a sale occurs. Unnamed sources say a deal could be announced within weeks after Mr. Melnyk filed a bid to receiver PricewaterhouseCoopers." This line is from the latest news release from Hemosol: "At this time there is no certainty as to whether the potential acquisition will result in a transaction being completed. If a transaction is completed, there is a reasonable likelihood that any plan filed by Hemosol would result in a substantial dilution of the equity of Hemosol held by the shareholders existing at that time."
Bullboard Posts